scholarly journals Clinical and pathogenetic features of myocardial infarction in patients with atrial fibrillation

2020 ◽  
pp. 31-39
Author(s):  
S.Y. Borodashkina ◽  
◽  
K.V. Protasov ◽  
Keyword(s):  
Myocardial Infarction ◽  
Atrial Fibrillation ◽  
Observational Studies ◽  
Risk Group ◽  
Clinical Manifestations ◽  
High Risk Group ◽  
Short Term ◽  
Invasive Treatment ◽  
Long Term Prognosis

Patients with myocardial infarction (MI) and atrial fibrillation (AF), the number of which is progressively increasing every year, make up a high-risk group for both recurrent cardiovascular events and bleeding; they require special attention from clinicians. The literature review provides data on features of pathogenesis and clinical manifestations of MI in patients with AF. The analysis of data on AF effect observational studies on short-term and long-term prognosis in patients with myocardial infarction was carried out. Mechanisms of occurrence, clinical features and prognostic value of postinfarction AF are considered. From the standpoint of modern clinical guidelines, information is presented on features of MI invasive treatment in combination with AF. Algorithms of anticoagulant and antiarrhythmic therapy in patients of this category are considered.

The choice of an oral anticoagulant

1972 ◽  
Vol 10 (7) ◽  
pp. 25-28 ◽  
Keyword(s):  
Myocardial Infarction ◽  
Atrial Fibrillation ◽  
Anticoagulant Therapy ◽  
Cerebral Ischaemia ◽  
Oral Anticoagulant ◽  
Short Term ◽  
Prevention And Treatment ◽  
Transient Cerebral Ischaemia

Some of the indications for anticoagulant therapy remain controversial, but they are widely used for the prevention and treatment of thrombosis and embolism after surgery1 and after myocardial infarction,2 in patients with atrial fibrillation, and in those with transient cerebral ischaemia.3 This article discusses the drugs available for long-term use. Those suitable for immediate and short-term use, heparin and arvin, will be discussed in the next issue.

scholarly journals A novel multi-omics-based identification of symptoms, comorbid conditions, and possible long-term complications in COVID-19

2020 ◽  
Author(s):  
Debmalya Barh ◽  
Sandeep Tiwari ◽  
Bruno Silva Andrade ◽  
Marianna E. Weener ◽  
Aristóteles Góes-Neto ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Observational Studies ◽  
Congenital Disorders ◽  
Comorbid Conditions ◽  
Short Term ◽  
Bidirectional Relationship ◽  
Long Term Consequences ◽  
Clinical Pictures ◽  
Kidney Liver

ABSTRACTTill date the comprehensive clinical pictures, comorbid conditions, and long-term complications of COVID-19 are not known. Recently using a multi-omics-based strategy, we have predicted the drugs for COVID-19 management with ∼70% accuracy. Here, using a similar multi-omics-based bioinformatics approach and three-ways of analysis, we identified the symptoms, comorbid conditions, and short, mid and possible long-term complications of COVID-19 with ∼90% precision. In our analysis (i) we identified 27 parent, 170 child, and 403 specific conditions associated with COVID-19. (ii) Among the specific conditions, 36 are viral and 53 short-term, 62 short to mid to long-term, 194 mid to long-term, and 57 are congenital conditions. (iii) At a cut off “count of occurrence” of 4, we found ∼ 90% of the enriched conditions are associated with COVID-19. (iv) Except the dry cough and loss of taste, all other COVID-19 associated mild and severe symptoms are enriched. (v) Cardiovascular, pulmonary, metabolic, musculoskeletal, neuropsychiatric, kidney, liver, and immune system disorders are found as top comorbid conditions. (vi) Specific diseases such as myocardial infarction, hypertension, COPD, lung injury, diabetes, cirrhosis, mood disorders, dementia, macular degeneration, chronic kidney disease, lupus, arthritis etc. along with several other diseases are also enriched as top candidates. (vii) Interestingly, many cancers and congenital disorders associated with COVID-19 severity are also identified. (viii) Arthritis, dermatomyositis, glioma, diabetes, psychiatric disorder, cardiovascular diseases having bidirectional relationship with COVID-19 are also found as top ranked conditions. Based on the accuracy (∼90%) of this analysis, long presence of SARS-CoV-2 RNA in human, and our previously proposed “genetic remittance” assumption, we hypothesize that all the identified comorbid conditions including the short-long-mid and mid-long non-communicable diseases (NCDs) could also be long-term consequences in COVID-19 survivors and warrants long-term observational studies.

scholarly journals Association Between Fasting Hyperglycemia and New-Onset Atrial Fibrillation in Patients With Acute Myocardial Infarction and the Impact on Short- and Long-Term Prognosis

2021 ◽  
Vol 8 ◽  
Author(s):  
Mingxing Li ◽  
Yingying Gao ◽  
Kai Guo ◽  
Zidi Wu ◽  
Yi Lao ◽  
...  
Keyword(s):  
Risk Factors ◽  
Myocardial Infarction ◽  
Atrial Fibrillation ◽  
Acute Myocardial Infarction ◽  
All Cause Mortality ◽  
Long Term Prognosis ◽  
Onset Atrial Fibrillation ◽  
New Onset

Background: The relationship between fasting hyperglycemia (FHG) and new-onset atrial fibrillation (AF) in patients with acute myocardial infarction (AMI) is unclear, and whether their co-occurrence is associated with a worse in-hospital and long-term prognosis than FHG or AF alone is unknown.Objective: To explore the correlation between FHG and new-onset AF in patients with AMI, and their impact on in-hospital and long-term all-cause mortality.Methods: We performed a retrospective cohort study comprising 563 AMI patients. The patients were divided into the FHG group and the NFHG group. The incidence of new-onset AF during hospitalization was compared between the two groups and sub-groups under different Killip grades. Logistic regression was used to assess the association between FHG and new-onset AF. In-hospital mortality and long-term all-cause mortality were compared among patients with FHG, AF, and with both FHG and AF according to 10 years of follow-up information.Results: New-onset AF occurred more frequently in the FHG group than in the NFHG group (21.6 vs. 9.2%, p < 0.001). This trend was observed for Killip grade I (16.6 vs. 6.5%, p = 0.002) and Grade II (17.1 vs. 6.9%, p = 0.005), but not for Killip grade III–IV (40 vs. 33.3%, p = 0.761). Logistic regression showed FHG independently correlated with new-onset AF (OR, 2.56; 95% CI, 1.53–4.30; P < 0.001), and 1 mmol/L increased in fasting glucose was associated with a 5% higher rate of new-onset AF, after adjustment for traditional AF risk factors. AMI patients complicated with both fasting hyperglycemia and AF showed the highest in-hospital mortality and long-term all-cause mortality during an average of 11.2 years of follow-up. Multivariate Cox regression showed FHG combined with AF independently correlated with long-term all-cause mortality after adjustment for other traditional risk factors (OR = 3.13, 95% CI 1.64–5.96, p = 0.001), compared with the group with neither FHG nor new-onset AF.Conclusion: FHG was an independent risk factor for new-onset AF in patients with AMI. AMI patients complicated with both FHG and new-onset AF showed worse in-hospital and long-term all-cause mortality than with FHG or AF alone.

Short- and Long-term Prognosis of Previous and New-onset Atrial Fibrillation in ST-segment Elevation Acute Myocardial Infarction

2015 ◽  
Vol 68 (1) ◽  
pp. 31-38 ◽  
Author(s):  
Luciano Consuegra-Sánchez ◽  
Antonio Melgarejo-Moreno ◽  
José Galcerá-Tomás ◽  
Nuria Alonso-Fernández ◽  
Ángela Díaz-Pastor ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Atrial Fibrillation ◽  
St Segment Elevation ◽  
St Segment ◽  
Short And Long Term ◽  
Long Term Prognosis ◽  
Onset Atrial Fibrillation ◽  
Elevation Acute Myocardial Infarction ◽  
New Onset

Association of shock index with short-term and long-term prognosis after ST-segment elevation myocardial infarction

2019 ◽  
Vol 30 (8) ◽  
pp. 575-583
Author(s):  
Gjin Ndrepepa ◽  
Salvatore Cassese ◽  
Erion Xhepa ◽  
Massimiliano Fusaro ◽  
Karl-Ludwig Laugwitz ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Shock Index ◽  
Short Term ◽  
St Segment Elevation ◽  
Segment Elevation Myocardial Infarction ◽  
St Segment ◽  
Long Term Prognosis

scholarly journals Implications of new-onset atrial fibrillation for in-hospital and long-term prognosis in patients with acute myocardial infarction: the CBD Bank study

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
W Yang ◽  
G Lip ◽  
H Li
Keyword(s):  
Myocardial Infarction ◽  
Atrial Fibrillation ◽  
Acute Myocardial Infarction ◽  
Independent Predictor ◽  
Cardiovascular Death ◽  
Long Term Follow Up ◽  
Long Term Prognosis ◽  
New Onset

Abstract Background Atrial fibrillation (AF) often coexists with coronary artery disease. Data on the incidence and prognostic impact of new-onset AF following acute myocardial infarction (AMI) with current optimal therapy are insufficient, especially in Asian populations. Purpose To investigate the incidence of new-onset AF following AMI and to assess its impact on in-hospital and long-term prognosis. Methods We included consecutive AMI patients between December 2012 and July 2019, and excluded those with prior known AF on presentation. New-onset AF was defined as newly detected AF during the index hospitalization following AMI. The primary outcomes comprised of all-cause death and cardiovascular death occurred during hospitalization; and all-cause death and cardiovascular death during long-term follow-up among those AMI survivors. Follow-up visits were routinely scheduled after discharge, at 1 month, 3 months, 6 months, 12 months and every 12 months thereafter. Results Of 3686 patients enrolled, new-onset AF was documented in 138 (3.7%) patients during a mean duration of hospitalization of 8.8±5.8 days. Independent risk factors of new-onset AF were age ≥75 years, left atrial diameter ≥40mm, high levels of cardiac troponin-I or high sensitive C reactive protein. During hospitalization, all-cause death occurred in 22 (15.9%) new-onset AF patients and 67 (1.9%) non-AF patients (p<0.001); cardiovascular death occurred in 19 (13.8%) new-onset AF patients and 58 (1.6%) non-AF patients (p<0.001). On multivariable logistic analysis, new-onset AF was an independent predictor of in-hospital all-cause death (OR 5.85, 95% CI: 3.24–10.55) and cardiovascular death (OR 5.44, 95% CI: 2.90–10.20). Apart from the in-hospital deaths, another 265 (7.7%) were lost to follow-up; thus, 3332 patients were included in the long-term follow-up analysis: 106 new-onset AF and 3226 non-AF patients. After a mean follow-up period of 1096.7±682.0 days, all-cause death occurred in 19 new-onset AF patients and 249 non-AF patients; corresponding rates were 8.08 (95% CI: 5.15–12.67) vs. 2.55 (95% CI: 2.25, 2.88) per 100 person-years, respectively (p<0.001). Cardiovascular death occurred in 11 new-onset AF patients and 150 non-AF patients; corresponding rates were 4.68 (95% CI: 2.59–8.45) vs. 1.53 (95% CI: 1.31–1.80) per 100 person-years, respectively (p=0.002). After multivariable Cox adjustment, there was no significant association between new-onset AF and long-term all-cause death (HR 1.45, 95% CI: 0.90–2.35) or cardiovascular death (HR 1.21, 95% CI: 0.65–2.26). Conclusion New-onset AF following AMI was an independent predictor of increased risk of in-hospital mortality, but had no independent association with long-term death. Funding Acknowledgement Type of funding source: None

Sign in / Sign up

Export Citation Format

Share Document